Last Updated: November 16, 2026

Details for Patent: 10,226,473

« Back to Dashboard


Which drugs does patent 10,226,473 protect, and when does it expire?

Patent 10,226,473 protects TLANDO and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 10,226,473
Title:High-strength testosterone undecanoate compositions
Abstract:The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
Inventor(s):Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
Assignee: Lipocine Inc
Application Number:US15/955,429
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

United States Patent 10,226,473: Claim Scope, Tlando Coverage, Expiration, and Oral Testosterone Undecanoate Patent Landscape

U.S. Patent No. 10,226,473 is a method-of-treatment patent covering oral testosterone undecanoate replacement therapy using two unit dosage forms administered twice daily, delivering approximately 450 mg of testosterone undecanoate per day and producing a serum testosterone concentration of approximately 300 to 1,100 ng/dL. The claims also protect specific lipid-based carrier systems and a partially dissolved formulation profile.

The patent is closely aligned with the dosing regimen for TLANDO, an oral testosterone undecanoate product approved by the FDA in 2022. The principal commercial risk is a product or method that copies the two-capsule, twice-daily regimen and uses a formulation satisfying the dissolution and carrier limitations.

What does U.S. Patent 10,226,473 protect?

The patent protects a method of testosterone replacement therapy rather than testosterone undecanoate as a molecule. Its broadest independent claims require the following combination:

Limitation Claim 1 Claim 12
Male patient Yes Yes
Testosterone deficiency or absence Yes Yes
Oral administration Yes Yes
Two unit dosage forms per administration Yes Yes
Twice-daily administration Yes Yes, with additional redundancy in claim 13
Daily testosterone undecanoate dose About 450 mg About 450 mg
Serum testosterone target About 300-1,100 ng/dL About 300-1,100 ng/dL
Measurement at steady state Yes No express steady-state requirement
Measurement 1-12 hours after a single dose Yes No
At least 5% undissolved testosterone undecanoate No Yes
At least 35% dissolved testosterone undecanoate No Yes

Claim 1 is principally a regimen and pharmacokinetic claim. Claim 12 is principally a regimen-plus-composition-state claim. The two claim groups overlap commercially but impose different infringement elements.

The patent does not claim every oral testosterone undecanoate product. A competing product could avoid literal infringement by using a different daily dose, different number of dosage units, a different administration frequency, or a formulation that does not meet the claimed dissolved/undissolved thresholds.

How broad is claim 1 of U.S. Patent 10,226,473?

Claim 1 has a relatively narrow but commercially meaningful combination of limitations. It requires all of the following:

  1. A male with a condition associated with deficient or absent endogenous testosterone.
  2. Oral administration.
  3. Two unit dosage forms per dose.
  4. Twice-daily administration.
  5. Approximately 450 mg of testosterone undecanoate per day.
  6. Serum testosterone testing at steady state.
  7. Testing 1 to 12 hours after a single dose.
  8. A serum testosterone concentration of approximately 300 to 1,100 ng/dL.

The claim is not limited to a named product, capsule shell, manufacturer, or specific excipient combination. It can therefore reach a competing oral testosterone undecanoate product if the product is used under the claimed dosing and monitoring protocol.

The claim also includes a result-oriented limitation: the regimen must provide a serum testosterone concentration within the stated range. That limitation may require patient-specific evidence. A product label prescribing the regimen would support an induced-infringement theory, but direct method infringement generally depends on performance of the claimed steps.

What does “about 450 mg” mean?

“About 450 mg” creates a range rather than an exact 450 mg requirement. The patent does not provide a universally fixed numerical boundary in the claim text. Courts generally interpret “about” in view of the specification, prosecution history, technical context, and evidence regarding measurement precision and formulation performance.

A regimen delivering 450 mg exactly is the clearest target. A regimen delivering materially more or less than 450 mg may avoid literal infringement, but the result would depend on the intrinsic record and any doctrine-of-equivalents analysis.

The TLANDO regimen is two 112.5 mg capsules taken twice daily, for a total of 450 mg of testosterone undecanoate per day. That dosing architecture closely tracks the core limitations of claims 1 and 12.[2]

How broad is claim 12 compared with claim 1?

Claim 12 omits two important limitations from claim 1:

  • It does not expressly require serum testosterone measurement at steady state.
  • It does not expressly require measurement 1 to 12 hours after a single dose.

Claim 12 adds a formulation-state limitation requiring:

  • At least 5% of the testosterone undecanoate to remain undissolved in the pharmaceutical carrier; and
  • At least 35% of the testosterone undecanoate to be dissolved in the carrier.

This creates a different enforcement profile. Claim 1 is more dependent on the prescribed clinical use and monitoring protocol. Claim 12 may be more dependent on formulation characterization, manufacturing records, analytical testing, and expert interpretation of “dissolved” versus “undissolved.”

Claim 12 is not necessarily broader overall. It is broader as to pharmacokinetic monitoring but narrower as to formulation composition state.

What formulation components are protected by the dependent claims?

Claims 2 through 10 and claims 14 through 21 identify categories of pharmaceutical carriers. They include:

Carrier category Claim(s)
Solubilizer and dispersant 2
Solidifying agent 3, 16
Monoglyceride 4, 17
Diglyceride 5, 18
Triglyceride 6, 19
Fatty acid 7, 14, 20
Medium-chain monoglycerides and diglycerides 8, 21
Tocopherol 9, 14
Hydrophilic surfactant 10, 15

These claims are dependent claims. Each incorporates all limitations of its parent claim. For example, claim 4 is not merely a claim to any testosterone undecanoate formulation containing a monoglyceride. It requires the full claim 1 method, including the two-unit, twice-daily, approximately 450 mg regimen and serum testosterone result, plus a monoglyceride carrier.

The same structure applies to claims 14 through 21, which depend from claim 12 and therefore also require the 5% undissolved and 35% dissolved formulation profile.

Why do the lipid excipient claims matter?

Testosterone undecanoate is highly lipophilic and has limited aqueous solubility. Lipid excipients can improve dispersion, solubilization, lymphatic uptake, and oral exposure. The claims target excipient classes that can influence absorption without claiming one narrowly defined molecular formulation.

The broad category terms create potential claim-construction disputes. Key issues include:

  • Whether a mixed lipid qualifies as a monoglyceride, diglyceride, or triglyceride.
  • Whether a medium-chain lipid must be separately identified in the finished dosage form.
  • Whether a tocopherol operates as a carrier, antioxidant, or both.
  • Whether a hydrophilic surfactant must be present at a particular concentration.
  • How the specification defines the dissolved and undissolved fractions.
  • Whether the 35% and 5% thresholds are measured before administration, after manufacture, or under a specified test method.

What is the relationship between the patent and TLANDO?

TLANDO contains 112.5 mg of testosterone undecanoate per capsule. The approved regimen is two capsules taken orally twice daily with food, producing a total daily dose of 450 mg of testosterone undecanoate.[2]

That regimen maps directly to the principal numerical and administration limitations of claims 1 and 12:

TLANDO characteristic Patent limitation
Two capsules per administration Two unit dosage forms
Twice daily Twice-daily dosing
112.5 mg per capsule 450 mg total daily dose
Oral testosterone undecanoate Oral TU composition
Male hypogonadism treatment Replacement therapy in a deficient male
Serum testosterone monitoring Claim 1 monitoring limitation

The FDA label requires serum testosterone measurement approximately 6 hours after the morning dose at steady state for dose adjustment. That timing falls within claim 1’s 1-to-12-hour window.[2]

The commercial alignment between the patent claims and the TLANDO label is strong. Claim 1 appears designed around the product’s dosing and monitoring protocol. Claim 12 adds a formulation limitation that would require comparison with the product’s technical composition and analytical data.

When does U.S. Patent 10,226,473 lose exclusivity?

The patent’s term should be determined from the official USPTO patent record, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension. The patent was issued on March 12, 2019.[1]

Public Orange Book materials identify U.S. Patent 10,226,473 in connection with TLANDO and report an expiration date in September 2027.[3] The commonly reported Orange Book expiration date is September 24, 2027.

The patent expiration date is separate from FDA regulatory exclusivity. TLANDO received FDA approval on March 27, 2022.[4] Its five-year new chemical entity exclusivity period generally runs through March 27, 2027, subject to the applicable FDA calculation. The patent therefore extends beyond the principal NCE exclusivity period by approximately six months.

Milestone Date
Patent issued March 12, 2019
TLANDO FDA approval March 27, 2022
Approximate NCE exclusivity end March 27, 2027
Reported expiration of U.S. 10,226,473 September 24, 2027

A patent expiration date does not guarantee immediate generic launch. An ANDA applicant must address all relevant Orange Book patents and satisfy FDA approval requirements. Conversely, expiration of this patent would not eliminate other patents covering TLANDO, its formulation, manufacturing process, or use.

What is the Orange Book status of U.S. Patent 10,226,473?

U.S. Patent 10,226,473 is listed in FDA Orange Book materials for TLANDO, the 112.5 mg oral testosterone undecanoate capsule.[3] The listing gives the patent practical importance in ANDA litigation and certification.

For a generic applicant, the principal pathways are:

  • Paragraph III certification, accepting delayed approval until patent expiration.
  • Paragraph IV certification, asserting that the listed patent is invalid, unenforceable, or not infringed.
  • A section viii statement, where applicable, seeking approval without the patented method of use.

Because the patent claims a dosing method rather than merely a product composition, a section viii strategy could be relevant only if the proposed labeling can omit the patented method and still support approval. That strategy would be difficult if the generic label necessarily instructs the same two-capsule, twice-daily, 450 mg regimen.

The FDA label itself does not establish infringement. It is evidence of the intended use and prescribed regimen. Patent liability depends on claim construction, the proposed labeling, actual use, and the asserted claims.

Which companies are challenging the patent?

A Paragraph IV filing is not necessarily public before the NDA holder files an infringement action. The ANDA applicant typically sends a notice letter to the NDA and patent holder, and litigation may follow under the Hatch-Waxman framework.[5]

The publicly material commercial parties associated with the patent and product are:

Entity Role
Lipocine, Inc. Originator and patent-rights holder associated with the TLANDO technology
Antares Pharma, Inc. Commercial partner for TLANDO before its acquisition
Halozyme Therapeutics, Inc. Acquired Antares Pharma
FDA Approved TLANDO and maintains Orange Book listings
Generic applicants Potential Paragraph III or Paragraph IV challengers

No specific generic challenger can be identified from the supplied claim text alone. A reliable litigation analysis must distinguish between a filed Paragraph IV action, an unpublicized ANDA filing, and a potential future challenge.

What patent litigation affects TLANDO and this patent?

The principal legal exposure would arise if a generic applicant files a Paragraph IV certification against U.S. Patent 10,226,473 and the patent holder brings an infringement action within 45 days. That action can trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court developments.[5]

Likely dispute issues include:

  1. Whether the proposed product label instructs two capsules twice daily.
  2. Whether the proposed dose is approximately 450 mg per day.
  3. Whether the generic formulation contains the claimed dissolved and undissolved fractions.
  4. Whether the claims are enabled across the full scope of the carrier categories.
  5. Whether “about 450 mg” and “about 300-1,100 ng/dL” are indefinite.
  6. Whether the serum range is an inherent result of the claimed regimen.
  7. Whether the patent’s method claims are anticipated by prior oral testosterone undecanoate studies.
  8. Whether the patent was properly listed for the approved product and indication.
  9. Whether a formulation change avoids the dependent carrier claims while retaining bioequivalence.

The claim structure gives the patent holder multiple theories. A challenger may avoid the specific carrier claims while still facing claims 1 and 12 if its label copies the regimen.

How does U.S. Patent 10,226,473 compare with competing oral testosterone products?

The three FDA-approved oral testosterone undecanoate products have different dose architectures and formulation platforms.

Product Sponsor Typical capsule strength Standard regimen Competitive relevance
TLANDO Antares/Halozyme and Lipocine 112.5 mg TU Two capsules twice daily Closest match to the patent
JATENZO Clarus Therapeutics 237 mg TU One capsule twice daily Different unit count and dose
KYZATREX Marius Pharmaceuticals 200 mg TU One capsule twice daily Different dose architecture

JATENZO and KYZATREX may avoid the literal “two unit dosage forms” limitation if their approved labels require one capsule per administration. They may still face separate patents covering oral testosterone undecanoate formulations, pharmacokinetic performance, or methods of use.

The patent therefore has greater product-specific relevance to TLANDO than to competing oral testosterone products.

What generic launch risks exist after patent expiration?

A generic launch before September 2027 would face the combined risks of patent litigation, FDA approval timing, and possible additional Orange Book patents. The most plausible launch scenarios are:

Scenario Commercial implication
Paragraph III certification Launch delayed until patent expiry
Paragraph IV challenge with settlement Launch date governed by settlement terms
Paragraph IV challenge with litigation win Earlier launch possible
Formulation design-around May avoid carrier claims but must satisfy FDA requirements
Label carve-out May avoid method claims if the FDA permits omission
Post-expiration launch Patent 10,226,473 no longer blocks the claimed method, but other rights may remain

A design-around that uses one dosage unit twice daily could avoid the two-unit limitation, but it would need to maintain acceptable exposure, food-effect performance, and bioequivalence. A different lipid carrier could avoid particular dependent claims but would not necessarily avoid claim 1 or claim 12.

How strong is the patent estate around TLANDO?

U.S. Patent 10,226,473 has meaningful commercial strength because it covers the product’s central dosing architecture rather than an optional formulation feature. Its strongest features are:

  • Exact alignment with the two-capsule, twice-daily TLANDO regimen.
  • A defined total daily dose of approximately 450 mg.
  • A serum testosterone target consistent with clinical monitoring.
  • Dependent claims directed to common lipid excipient categories.
  • Orange Book listing, which creates a Hatch-Waxman litigation pathway.

Its vulnerabilities are equally identifiable:

  • The dose and serum range use “about.”
  • Claim 1 requires a clinical serum concentration result that may vary across patients.
  • Claim 12 depends on analytical definitions of dissolution.
  • Prior-art oral testosterone and lipid-formulation literature may be relevant to validity.
  • Competitors using different capsule counts or dose strengths may avoid the core regimen limitations.
  • Additional patent families may be required to protect the product after this patent expires.

The patent is strongest against a generic that copies TLANDO’s label and formulation. It is weaker against a competitor using a materially different dose architecture or a formulation outside the claimed carrier and dissolution parameters.

What manufacturing and intellectual-property barriers remain?

The claims create manufacturing risks beyond the active ingredient itself. A competing manufacturer must control:

  • Testosterone undecanoate loading.
  • Lipid excipient identity and ratio.
  • Solubilization and dispersion behavior.
  • The dissolved and undissolved fraction.
  • Capsule fill uniformity.
  • Stability of the lipid matrix.
  • Food-effect performance.
  • Batch-to-batch serum exposure.
  • Bioequivalence to the reference product.

The formulation claims may be difficult to evaluate from public product information alone. A generic applicant would typically rely on formulation development data, analytical methods, and regulatory confidentiality. Patent litigation can expose those issues through discovery.

Geographically, U.S. Patent 10,226,473 affects U.S. manufacture, importation, sale, offer for sale, and use under U.S. law. Parallel patent families in Europe, Canada, Japan, or other markets must be analyzed separately. The U.S. patent does not establish protection in those jurisdictions.

Key Takeaways

  • U.S. Patent 10,226,473 is a method patent covering oral testosterone undecanoate replacement therapy.
  • The central regimen is two unit dosage forms twice daily, delivering approximately 450 mg per day.
  • Claim 1 adds steady-state serum monitoring 1 to 12 hours after dosing and a 300-to-1,100 ng/dL serum testosterone target.
  • Claim 12 adds a formulation requirement of at least 5% undissolved and at least 35% dissolved testosterone undecanoate.
  • Dependent claims cover lipid carriers, including mono-, di-, and triglycerides, fatty acids, tocopherols, surfactants, and solidifying agents.
  • The claim set closely tracks the TLANDO 112.5 mg, two-capsule, twice-daily regimen.
  • The reported Orange Book expiration date is September 24, 2027.
  • JATENZO and KYZATREX use different dose architectures and may not literally satisfy the two-unit limitation.
  • The principal generic risk is a Paragraph IV challenge against the dosing and formulation claims.
  • The patent is commercially strongest against a copycat TLANDO product and weaker against a product using a different capsule count, dose, or carrier system.

Frequently Asked Questions

Does U.S. Patent 10,226,473 cover testosterone undecanoate itself?

No. The patent claims methods of administering testosterone undecanoate and selected formulation characteristics. It does not broadly claim the testosterone undecanoate molecule.

Can a one-capsule, twice-daily product avoid the patent?

It may avoid the literal “two unit dosage forms” limitation, but the conclusion depends on the full claim set, product labeling, formulation, and any doctrine-of-equivalents analysis.

Does the 450 mg daily dose have to be exact?

No. The claims use “about 450 mg.” The legally relevant range must be determined from the patent specification, prosecution history, and technical evidence.

Is serum testosterone testing required for every asserted claim?

No. Claim 1 expressly requires testing at steady state 1 to 12 hours after a dose. Claim 12 does not expressly include those timing and steady-state limitations, although it requires the serum testosterone result.

Does patent expiration end all exclusivity for TLANDO?

No. Expiration of U.S. Patent 10,226,473 removes that patent as a barrier, but other patents, regulatory requirements, settlements, manufacturing rights, or separate intellectual-property protections may remain.

Sources

  1. United States Patent and Trademark Office. (2019). U.S. Patent No. 10,226,473, oral testosterone undecanoate formulations and methods of use thereof.
  2. U.S. Food and Drug Administration. (2022). TLANDO (testosterone undecanoate) capsules: Prescribing information.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  4. U.S. Food and Drug Administration. (2022, March 27). FDA approves TLANDO for testosterone replacement therapy in adult males.
  5. Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,226,473

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Verity TLANDO testosterone undecanoate CAPSULE;ORAL 208088-001 Mar 28, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,226,473

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2012075081 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.